A Phase II Trial of Radiation Plus Temozolomide Followed by Adjuvant Temozolomide and Poly-ICLC in Patients With Newly Diagnosed Glioblastoma Multiforme.
Phase of Trial: Phase II
Latest Information Update: 23 May 2018
At a glance
- Drugs Poly ICLC (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 02 May 2012 Actual patient number is 97 according to ClinicalTrials.gov.
- 02 May 2012 Actual end date changed from Aug 2009 to Apr 2010 as reported by ClinicalTrials.gov.
- 15 Jul 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.